Alexander Maximilian Aldejohann

Dr. Alexander Maximilian Aldejohann

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2022 in Mycoses
Verified
Journal Article
Open access
CHCarl Hinrichs
Carl Hinrichs
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
BGBarbara Graf
Barbara Graf
CGChristine Geffers
Christine Geffers
BWBeate Weikert
Beate Weikert
OKOliver Kurzai
Oliver Kurzai
Background: Candida auris a frequently multidrug‐resistant yeast species that poses a global health threat due to its high potential for hospital outbreaks. While C. auris has become endemic in parts of Asia and Africa, transmissions have so far rarely been reported in Western Europe except for Great Britain and Spain. We describe the first documented patient‐to‐patient transmission of C. auris in Germany in a COVID‐19 intensive care unit (ICU) and infection control measures implemented to prevent further spread of the pathogen.Methods: Identification of C. auris was performed by MALDI‐TOF and confirmed by internal transcribed spacer (ITS) sequencing. Antifungal susceptibility testing was carried out. We conducted repeated cross‐sectional examinations for the presence of C. auris in the patients of the affected ICU and investigated possible routes of transmission.Results: The index patient had been transferred to Germany from a hospital in Northern Africa and was found to be colonised with C. auris. The contact patient developed C. auris sepsis. Infection prevention and control (IPC) measures included strict isolation of the two C. auris patients and regular screening of non‐affected patients. No further case occurred during the subsequent weeks. Reusable blades used in video laryngoscope‐guided intubation were considered as the most likely vehicle of transmission.Conclusions: In view of its high risk of transmission, vigilance regarding C. auris colonisation in patients referred from endemic countries is crucial. Strict and immediate IPC measures may have the potential to prevent C. auris outbreaks.

7 February 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
CMCarolina Menner
Carolina Menner
NTNadja Thielemann
Nadja Thielemann
RMRonny Martin
Ronny Martin
GWGrit Walther
Grit Walther
OKOliver Kurzai
Oliver Kurzai
Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- Candida activity. We challenged IBX with a library of 192 pheno-/genotypically echinocandin-resistant Candida isolates, focusing on the substance susceptibility, its activity on certain FKS hotspot (HS) mutated strains, and applying WTULs (wild-type upper limits). Therefore, a 9-year-old strain and patient data collection provided by the German National Reference Center for Invasive Fungal Infections were analyzed. Species identification was confirmed through ITS-sequencing. Molecular susceptibility testing was performed by sequencing HS of the FKS gene. Anidulafungin (AND) and IBX EUCAST-broth-microdilution was conducted. The four most common echinocandin-resistance mediating mutations were found in Candida glabrata [112/192 isolates; F659-(43×) and S663-(48×)] and Candida albicans [63/192 isolates; F641-(15×) and S645-(39×)]. Mutations at the HS-start sequence were associated with higher IBX MIC-values (F659 and F641 (MIC 50/90 mg/L: >4/>4 and 2/4 mg/L) in comparison to AND (F659 and F641 (MIC 50/90: 1/4 and 0.25/1 mg/L). MIC-values in HS-center mutations were almost equal [MIC50/90 in S663: 2/4 (AND and IBX); in S645: 0.5/1 (AND) and 0.25/1 (IBX) mg/L]. In total, 61 vs 78 of 192 echinocandin-resistant isolates may be classified as IBX wild type by applying WTULs, whereas the most prominent effect was seen in C. albicans [48% (30/63) vs 70% (44/63)]. IBX shows in vitro activity against echinocandin-resistant Candida and thus is an addition to the antifungal armory. However, our data suggest that this effect is more pronounced in C. albicans and strains harboring mutations, affecting the HS-center.

4 June 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
EGEnrico Garbe
Enrico Garbe
AUAhsan Ullah
Ahsan Ullah
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
OKOliver Kurzai
Oliver Kurzai
Slavica JanevskaSlavica Janevska
Slavica Janevska
GWGrit Walther
Grit Walther
The genus Fusarium includes several trans-kingdom pathogens, infecting plants, animals, and humans, with widespread occurrence. Invasive Fusarium infections are often destructive due to their prevalence in critically ill patients. Furthermore, severe superficial infections, like keratitis or endophthalmitis with potential loss of vision, are rising in incidence globally. Infections are difficult to treat due to the intrinsic resistance of Fusarium against echinocandins and often high minimal inhibitory concentrations (MICs) for azoles. In this article, we assessed the in vitro activity of the novel antifungals olorofim, manogepix, rezafungin, and ibrexafungerp, as well as the established but nonstandard drugs, natamycin and terbinafine, against a large set of molecularly identified clinical Fusarium isolates via EUCAST microdilution. The tested isolates represent the clinically most relevant species of the F. solani (FSSC), F. oxysporum (FOSC), F. fujikuroi (FFSC), F. incarnatum-equiseti (FIESC), F. dimerum (FDSC), and F. redolens (FRSC) species complexes. While rezafungin and ibrexafungerp showed no effect on the Fusarium spp. tested, a general antifungal susceptibility of Fusarium against natamycin and manogepix was found. Specific profiles were detailed for terbinafine and olorofim. While species from the FDSC, FSSC, and FIESC show high MICs for olorofim, specific susceptibility rates were found for species of the FFSC and FOSC. Furthermore, we report specific susceptibilities for terbinafine against FDSC, FFSC, and FOSC species. These findings of complex- and species-specific olorofim and terbinafine in vitro susceptibilities highlight the need for diagnostics below genus level.

1 June 2021 in Medical Mycology Case Reports
Verified
Journal Article
Open access
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
JTJohanna Theuersbacher
Johanna Theuersbacher
LHLukas Haug
Lukas Haug
OLOlga S. Lamm
Olga S. Lamm
GWGrit Walther
Grit Walther
DKDaniel Kampik
Daniel Kampik
We present a case of Kluyveromyces marxianus keratitis nine months after Descement's membrane endothelial keratoplasty (DMEK) in a patient with Fuchs endothelial disease. Endothelial scraping revealed this rare yeast infection at the interface between graft and host cornea. Immediate antifungal treatment with intracameral and corneal intrastromal injections of voriconazole and amphotericin B remained unsuccessful, requiring penetrating keratoplasty. This case highlights the challenging management of keratomycosis in patients with endothelial grafts.

25 August 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
AMAntonio Uribe Munoz
Antonio Uribe Munoz
MFMiriam A. Füller
Miriam A. Füller
GWGrit Walther
Grit Walther
OKOliver Kurzai
Oliver Kurzai
Andreas Hermann GrollAndreas Hermann Groll
Andreas Hermann Groll
Mucormycosis is a rare invasive fungal disease in pediatric patients with hematological malignancies and is associated with poor outcomes. We present a fulminant and ultimately fatal case of rhino-orbito-cerebral mucormycosis, addressing important issues including clinical signs and symptoms, diagnostic approaches and the challenges of timely diagnosis. The patient was an 11-year old girl undergoing re-induction chemotherapy for Central Nervous System relapse of B-cell precursor acute lymphoblastic leukemia. She presented six days into the second course of chemotherapy in profound neutropenia with aggravating headaches, painful abducens nerve palsy and anisocoria. At first (day −3), no significant radiological or ophthalmological correlations were found, and methyl–prednisolone was started due to suspected vasculitis following ICU admission. After further clinical deterioration, a second MRI scan (day 0) revealed a prolonged occlusion of the left carotid artery, which was successfully stented in a neuroradiological intervention (day +1). However, during the next day the child developed clinical signs indicating severe cerebral dysfunction. An emergency CT scan showed complete infarction of the left hemisphere including a progredient perfusion deficit and beginning brain edema. Based on the unfavorable prognosis, best supportive care was initiated, and the patient deceased on day +2. Pathological and microbiological workup identified thrombotic infarction in all major cerebral arteries. While microscopy was suspicious for mucormycosis, nested PCR from retained blood specimens confirmed the genus Lichtheimia. Final NGS on brain tissue led to the identification of Lichtheimia ramosa. This case illustrates the rapidity and severity of Mucorales infection. It shows the importance of early clinical suspicion and the need for an aggressive laboratory testing algorithms. The stratification of risk factors and definition of red flags may be a future task fighting these infections.

22 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NTNadja Thielemann
Nadja Thielemann
SSSara Leal Siliceo
Sara Leal Siliceo
MRMonika Rau
Monika Rau
ASAnnika Schoeninger
Annika Schoeninger
NRNathalie Reus
Nathalie Reus
OKOliver Kurzai
Oliver Kurzai
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in Western countries. Progression to metabolic dysfunction-associated steatohepatitis (MASH) occurs when fat accumulation in the liver triggers Th17 activation and other inflammatory processes. In this study, we identify the IL17A rs2275913 minor allele variant as a risk factor for fibrosis progression in MASLD patients. In patients with advanced fibrosis, we also observed an increased abundance of fungal CTG species including Candida albicans and Debaryomyces hansenii , which are potent triggers of Th17 responses. Integrating genetic risk-predisposition and mycobiome composition, we show in ex vivo T cell stimulation assays, that donors carrying the minor allele variant of IL17A rs2275913 secreted significantly higher IL-17A levels in response to CTG species. Additionally, MASH patients carrying the IL17A rs2275913 risk allele have elevated Th17/Treg ratios in peripheral blood. Taken together, our data indicate that genetic predisposition for enhanced Th17 responses in the context of mycobiome dysbiosis can trigger MASH progression and liver fibrosis. Graphical This Graphical Abstract was created with BioRender.com . Brief summary: Increased antifungal immune responses triggered by gut mycobiome dysbiosis in genetically predisposed patients can lead to severe stages of metabolic dysfunction-associated steatotic liver disease.